Description
The
C-peptide [125I] IRMA system provides a direct quantitative
determination of C-peptide in human serum and urine. C-peptide can be
assayed in the range of 0-30 ng/ml (in human serum) and 0-300 ng/ml (in
urine) using 50 µl serum samples. Each kit contains materials sufficient
for 100 assay tubes permitting the construction of one standard curve
and the assay of 42 unknowns in duplicate.
Introduction
C-peptide
(connective peptide) is a polypeptide with a molecular weight of 3600,
containing 31 amino acid. It derives from proinsulin produced in
pancreatic beta cells. Proinsulin is converted to insulin and C-peptide,
which are then secreted into the portal blood in an equimolar quantity.
Contrary to insulin, C-peptide is not extracted by the liver, but enters
the systemic circulation.
In the
diagnosis of diabetes, C-peptide is a more reliable indicator of insulin
secretion than is the insulin itself. Furthermore, the concentration of
C-peptide is not affected by interference from insulin antibodies often
present in patients receiving insulin therapy. The assessment of
residual endogenous insulin secretion by the measurement of C-peptide is
an indispensable tool for the diagnosis and treatment of diabetes
mellitus.
Principle of method
The technology
uses two high affinity monoclonal antibodies in an immunoradiometric
assay (IRMA) system. It offers an increased level of sensitivity and
specificity compared with conventional RIA methods.
The
125I labelled signal-antibody binds to an epitope of the
C-peptid molecule, which is different from that recognized by the
unlabelled capture-antibody. The two antibodies react simultaneously
with the antigen present in standards or samples which leads to the
formation of a capture antibody - antigen - signal antibody complex,
also referred to as a “sandwich”.
During
a 3 hour incubation period with continuous agitation immuno-complex is
immobilised on the reactive surface of test tubes. Reaction mixture is
then discarded, test tubes are washed exhaustively, and the
radioactivity is measured in a gamma counter.
The
concentration of antigen is directly proportional to the radioactivity
measured in test tubes. By constructing a calibration curve plotting
binding values against a series of standards containing known amount of
C-peptide, the unknown concentration of C-peptide in patient samples can
be determined.
Contents of the kit
|
1 bottle |
TRACER, ready to use.
21 ml, containing less than 740 kBq 125I-labelled
anti-C-peptide and biotin-labelled anti-C-peptide in buffer
containing proteins, 0.1% sodium azide, red colored. |
|
6 vials |
STANDARD (S0-S5)
S0 ready for use. 2.5 ml, human serum
containing 0.1% NaN3.
(S1-S5) lyophilized. 0.5 ml, human serum containing 0.1%
NaN3.
Conc.: 0, 0.25, 0.9, 3, 9, 30 ng/ml. |
|
1 vial |
CONTROL SERUM, lyophilized,
0.5 ml human serum, containing 0.1% NaN3.
The concentration of control serum is specified in the quality
certificate enclosed. |
|
2 boxes |
COATED TUBE, ready for use.
2X50 plastic tubes, coated with streptavidin. |
|
1 bottle |
WASH BUFFER CONCENTRATE
20 ml, with 0.1% NaN3.
Dilute with 700 ml distilled water before use. |
|
1 pc |
Quality certificate |
|
1 pc |
Pack leaflet |
Materials, tools and equipment required
Test
tube rack
Precision pipettes with disposable tip (20 µl if urine is assayed, 50
µl, 200 µl, 1.5 ml)
Shaker
Plastic foil
Gamma counter
Absorbent tissue
Recommended
tools and equipment
Repeating pipettes
Dispenser with reservoir (instead of the 1.5 ml pipette)
Specimen collection and storage
Serum
samples can be prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored at 2-8 °C if the
assay is carried out within 24 hours, otherwise aliquots should be
prepared and stored deep frozen (-20 °C). Do not store serum samples
longer than 2 months. Do not use lipemic, hemolyzed or turbid specimens.
Frozen samples should be thawed and thoroughly mixed before assaying.
Repeated freezing and thawing should be avoided.
24-hour urine
should be collected by an immediate freezing, then combining, the daily
portions taken. Do not store urine samples longer than 2 months. For use
in the assay, frozen urine should be thawed, mixed thoroughly, and
diluted 10-fold. Dilute 20 µl urine with 180 µl zero standard.
Preparation of reagents, storage
Store
the reagents between 2-8 °C after opening. At this temperature reagent
(except reconstituted standard and control) is stable until expiry date.
The actual expiry date is given on the package label and in the quality
certificate.
Add 0.5 ml
distilled water to the lyophilised standard and control serum, and mix
gently with shaking or vortexing (foaming should be avoided). Ensure
that complete dissolution is achieved, and allow the solution to
equilibrate at room temperature for at least 20 minutes.
For repeated
use the rest of reagent can be stored at -20 °C for two months. It is
not recommended to expose the same standard vial to more than two
freeze-melting cycles.
Add the wash
buffer concentrate to 700 ml distilled water. The diluted solution can
be stored at 2-8 °C until expiry date of the kit.
CAUTION!
Equilibrate all reagents and serum samples to room temperature. Mix all
reagents and samples thoroughly before use. Avoid excessive foaming.
Assay procedure
(For a quick
guide, refer to Table 1.)
|
1 |
Label coated tubes in duplicate for each standard
(S0-S5), control serum (C) and samples (P). Optionally, label
two test tubes for total count (T). |
|
2 |
Pipette 50 µl each of STANDARD (S0-S5), CONTROL (C) and
SAMPLES (P) into the properly labelled tubes.
|
|
3 |
Pipette 200 µl of TRACER into each tube.
|
|
4 |
Gently vortex all tubes. Seal all tubes with a plastic
foil. If optional total counts tubes are also prepared, place
them separately from others. |
|
5 |
Fix the test tube rack firmly onto the shaker plate. Turn
on the shaker and adjust an adequate speed such that liquid is
constantly rotating or shaking in each tube. Incubate tubes for
3 hours at room temperature. (Note: The efficient rotation
is a critical factor to achieve good performance. An uneven or
incomplete shaking may result in a serious error. Never use a
rack type with open hole.) |
|
6 |
Add 1.5 ml diluted wash buffer to each tube and decant
the supernatant from all tubes by the inversion of the rack. In
the upside down position place the rack on an absorbent paper
for 2 minutes. |
|
7 |
Repeat Step 6. |
|
8 |
Repeat Step 6. (The third washing step can
be omitted. See notes on the effect of this option later.)
|
|
9 |
Count each tube for at least 60 seconds in a gamma
counter. |
Table 1.
Assay Protocol, Pipetting Guide (all volumes in microliters)
|
Tubes |
T |
S0-S5 |
P |
C |
|
Standard |
|
50 |
|
|
|
Sample |
|
|
50 |
|
|
Control |
|
|
|
50 |
|
Tracer |
200 |
200 |
200 |
200 |
|
Vortex
mix
Rotate for 3 hours at room temperature. |
|
Wash
Buffer |
|
1500 |
1500 |
1500 |
|
Decant
the fluid and blot on filter paper. |
|
Wash
Buffer |
|
1500 |
1500 |
1500 |
|
Decant
the fluid and blot on filter paper. |
|
Wash
Buffer |
|
1500 |
1500 |
1500 |
|
Decant
the fluid and blot on filter paper. |
|
Count radioactivity (60 sec/tube) |
|
Calculate the results |
Table 2.
Typical Assay Data
| |
cpm
1 |
cpm
2 |
cpm
mean |
B0 / T %
|
C-peptide
ng/ml |
|
Total |
273835 |
274213 |
274024 |
|
- |
|
S0 |
74 |
68 |
71 |
0 |
- |
|
S1 |
1363 |
1378 |
1370 |
0.47 |
- |
|
S2 |
4744 |
4815 |
4780 |
1.72 |
- |
|
S3 |
17158 |
18023 |
17591 |
6.39 |
- |
|
S4 |
50937 |
53632 |
52285 |
19.05 |
- |
|
S5 |
115771 |
118580 |
117176 |
42.74 |
- |
|
C |
27956 |
26006 |
26981 |
|
4.5 |
Figure 1
A typical standard curve
(Do not use to calculate unknown samples)
Calculation of results
Calculate the
average CPM for each pair of assay tubes. Draw the standard curve by
plotting mean CPM of each standard level (ordinate) against the
respective concentration, except for 0 standard (abscissa) using log-log
graph paper.
Obtain sample
concentration by interpolation of sample counts on the standard curve.
For
computerized calculations and/or quality assessment normalized specific
binding values, rather than cpm values are used. Specific binding values
can be calculated for each standard and sample according to the
following equation:
| |
S1-5 [C, P] (cpm) – S0(cpm) |
|
|
B/T (%) = |
—————————— |
x 100 |
| |
T (cpm) |
|
Characterization of the assay
Performance
parameters have been determined under ideal experimental conditions; by
using fresh tracers, and a 3-step washing protocol. The use of a 2-step
washing procedure will only affect the analytical sensitivity.
Calibration
Standards are
calibrated against the WHO Ref. Prep., Code 84/510.
Assay
parameters
|
NSB / T |
|
< 0.05% (< 0.08% with 2-step wash) |
|
Bmax / B0 |
|
> 35% |
Sensitivity
Analytical sensitivity: 0.0056 ng/ml (0.0186 with the 2-step
washing procedure).
It is defined
as the concentration of C-peptide equivalent to the mean CPM of 20
replicates of the zero standard.
Functional
sensitivity: 0.105 ng/ml.
It is defined
as the value extra-polated to 20% of the inter-assay imprecision profile
obtained from 10 independent runs on patient samples with low endogenous
C-peptide concentration.
Hook
effect
There is no
high dose “hook effect” up to a C-peptide concentration of 90 ng/ml.
Specificity
Cross
reactivity values are defined as the mass ratio of cross-reacting agent
versus C-peptide, belonging to the same binding rate. Based on the ratio
proinsulin / insulin under physiologic conditions (about 5%), the
potential error contributed by proinsulin must be less than 2-4%.
|
Cross-reacting substance |
%
cross-reaction |
|
Human
insulin |
< 0.04 |
|
Proinsulin |
27.1 |
Precision and reproducibility
7 samples with
20 replicates in 1 assay run, and with duplicates in 12 runs were
measured to determine intra-assay and inter-assay precision,
respectively. Values obtained are shown below.
|
Intra-assay |
Inter-assay |
|
Mean
(ng/ml) |
CV % |
mean
(ng/ml) |
CV % |
|
0.52 |
4.87 |
0.52 |
3.31 |
|
1.55 |
2.12 |
1.41 |
4.65 |
|
2.33 |
5.03 |
3.03 |
4.07 |
|
3.81 |
3.56 |
3.10 |
5.88 |
|
5.64 |
2.09 |
4.36 |
2.28 |
|
7.57 |
5.09 |
6.57 |
3.25 |
|
23.46 |
4.04 |
11.96 |
3.96 |
Recovery
Recovery was defined as the measured increase expressed as percent of
expected increase upon spiking serum samples with known amount of
C-peptide. Values for 9 serum pools spiked with C-peptide at 3 levels
were as follows: 97.2 ± 8.5%
Dilution test
4 samples were
measured in a series of dilution (2, 4, 8, 16-fold) with zero-standard.
The following equation obtained for measured (Y) versus expected (X)
concentration demonstrates the good linearity:
y =
1.014x – 0.011; R = 0.9973; n = 16
Expected values
It is
recommended that each laboratory establish its own reference intervals.
| – |
morning sera, fasting healthy donors (N = 27) |
| |
1.77 ± 0.62 ng/ml, min. 1.07 – max. 3.51 ng/ml |
| – |
daily sera, healthy donors (N = 71) |
| |
4.88 ± 0.26 ng/ml, min. 1.37 – max. 11.8 ng/ml |
| – |
morning urine, fasting healthy donors (N = 29) |
| |
35.8 ± 19.2 ng/ml, min. 2.72 – max. 78.3 ng/ml |
Results
obtained should only be interpreted in the context of the overall
clinical picture. None of in vitro diagnostic kits can be used as the
one and only proof of any disease or disorder.
Conversion of values
1 nmol/l =
3.617 ng/ml
1 ng/ml = 0.276 nmol/l
Additional information
Components
from various lots or from kits of different manufacturers should not be
mixed or interchanged.
Precaution
Radioactivity
This product
contains radioactive material. It is the responsibility of the user to
ensure that local regulations or code of practice related to the
handling of radioactive materials are satisfied.
Biohazard
Human blood
products used in the kit have been obtained from healthy human donors.
They were tested individually by using approved methods (EIA, enzyme
immunoassay), and were found to be negative, for the presence of both
Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B
surface Antigen (HBsAg).
Care should
always be taken when handling human specimens to be tested with
diagnostic kits. Even if the subject has been tested, no method can
offer complete assurance that Hepatitis B Virus, Human Immunodeficiency
Virus (HIV-1), or other infectious agents are absent. Human blood
samples should therefore be handled as potentially infectious
materials.
Chemical hazard
Components
contain sodium azide as an antimicrobial agent. Dispose of waste by
flushing with copious amount of water to avoid build-up of explosive
metallic azides in copper and lead plumbing. The total azide present in
each pack is 66 mg.
 |
Use by |
 |
In vitro diagnostic medical device |
 |
Control |
 |
Batch code |
 |
Manufacturer |
 |
Standard |
 |
Caution, consult accompanying documents |
 |
Radioactive material |
 |
Coated tube |
 |
Biological risk |
 |
Temperature limitation
Store between 2-8 °C |
 |
Tracer |
 |
Consult instructions for use |
 |
Catalogue number |
 |
Wash buffer |
|